{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T20:45:29Z","timestamp":1746477929912},"reference-count":25,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2003,9,1]],"date-time":"2003-09-01T00:00:00Z","timestamp":1062374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2003,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            We employed a murine model to test the concept of using an aerosolized, long-acting antiviral drug to protect humans against smallpox. We previously showed that a low dose of aerosolized cidofovir (HPMPC [Vistide]) was highly protective against subsequent aerosolized cowpox virus challenge and was more effective than a much larger dose of drug given by injection, suggesting that aerosolized cidofovir is retained in the lung. Because the nephrotoxicity of cidofovir is a major concern in therapy, delivering the drug directly to the respiratory tract might be an effective prophylactic strategy that maximizes the tissue concentration at the site of initial viral replication, while minimizing its accumulation in the kidneys. In the present study, we found that treating mice with aerosolized\n            <jats:sup>14<\/jats:sup>\n            C-labeled cidofovir (\n            <jats:sup>14<\/jats:sup>\n            C-cidofovir) resulted in the prolonged retention of radiolabeled drug in the lungs at levels greatly exceeding those in the kidneys. In contrast, subcutaneous injection produced much higher concentrations of\n            <jats:sup>14<\/jats:sup>\n            C-cidofovir in the kidneys than in the lungs over the 96-h time course of the study. As further evidence of the protective efficacy of aerosolized cidofovir, we found that aerosol treatment before or after infection was highly protective in mice challenged intranasally with cowpox virus. All or nearly all mice that were treated once by aerosol, from 2 days before to 2 days after challenge, survived intranasal infection, whereas all placebo-treated animals died.\n          <\/jats:p>","DOI":"10.1128\/aac.47.9.2933-2937.2003","type":"journal-article","created":{"date-parts":[[2003,8,22]],"date-time":"2003-08-22T21:07:12Z","timestamp":1061586432000},"page":"2933-2937","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":20,"title":["Aerosolized Cidofovir Is Retained in the Respiratory Tract and Protects Mice against Intranasal Cowpox Virus Challenge"],"prefix":"10.1128","volume":"47","author":[{"given":"Chad J.","family":"Roy","sequence":"first","affiliation":[{"name":"Department of Aerobiology and Product Evaluation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Baker","sequence":"additional","affiliation":[{"name":"Department of Viral Therapeutics, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Washburn","sequence":"additional","affiliation":[{"name":"Stillmeadow Corp., Sugarland, Texas 77478"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Bray","sequence":"additional","affiliation":[{"name":"Biodefense Clinical Research Branch, Office of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(02)00196-1"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(01)00220-0"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/315190"},{"key":"e_1_3_2_5_2","first-page":"738","volume":"24","year":"1996","unstructured":"Cundy, K. C., Z. H. Li, M. J. Hitchcock, and W. A. Lee. 1996. Pharmacokinetics of cidofovir in monkeys: evidence for a prolonged elimination phase representing phosphorylated drug. Drug Metab. Dispos.24:738-744.","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0166-3542(97)00022-3","volume":"35","year":"1997","unstructured":"Cundy, K. C., G. Lynch, and W. A. Lee. 1997. Bioavailability and metabolism of cidofovir following topical administration to rabbits. Antivir. Res.35:113-122.","journal-title":"Antivir. Res."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199936020-00004"},{"key":"e_1_3_2_8_2","first-page":"745","volume":"24","year":"1996","unstructured":"Cundy, K. C., A. Bidgoo, G. Lynch, J. Shaw, L. Griffin, and W. A. Lee. 1996. Pharmacokinetics, bioavailability, metabolism and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Drug Metab. Dispos.24:745-752.","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(02)00008-6"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0165-6147(02)02091-6","volume":"23","year":"2002","unstructured":"De Clercq, E. 2002. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol. Sci.23:456-458.","journal-title":"Trends Pharmacol. Sci."},{"key":"e_1_3_2_11_2","unstructured":"Fenner F. D. A. Henderson I. Arita Z. Jezek and I. D. Ladnyi. 1988. Smallpox and its eradication. World Health Organization Geneva Switzerland."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011023431801"},{"key":"e_1_3_2_13_2","first-page":"488","volume":"4","year":"1998","unstructured":"Henderson, D. A. 1998. Bioterrorism as a public health threat. 1998. Emerg. Infect. Dis.4:488-492.","journal-title":"1998. Emerg. Infect. Dis."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.22.2127"},{"key":"e_1_3_2_15_2","first-page":"197","volume":"41","year":"1992","unstructured":"Ho, H. T., K. Woods, J. Bronson, H. De Boeck, J. Martin, and M. Hitchcock. 1992. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol. Pharmacol.41:197-202.","journal-title":"Mol. Pharmacol."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.3.1205-1210.2001"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/44.2.97"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.5858\/2000-124-0362-AMMOAT"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/095632029700800101"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/08958370390205092"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(01)00159-0"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(00)00105-4"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.5.1329-1335.2002"},{"key":"e_1_3_2_24_2","first-page":"1561","volume":"3","year":"2002","unstructured":"Snoeck, R., and E. de Clercq. 2002. Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients. Curr. Opin. Investig. Drugs3:1561-1566.","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(95)00829-2"},{"key":"e_1_3_2_26_2","first-page":"669","volume":"43","year":"1970","unstructured":"Wehrle, P. F., P. Posch, K. Richter, and D. A. Henderson. 1970. An air-borne outbreak of smallpox in a German hospital and its significance with respect to other recent outbreaks in Europe. Bull. W. H. O.43:669-679.","journal-title":"Bull. W. H. O."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.9.2933-2937.2003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.9.2933-2937.2003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:27:43Z","timestamp":1645468063000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.47.9.2933-2937.2003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2003,9]]}},"alternative-id":["10.1128\/AAC.47.9.2933-2937.2003"],"URL":"https:\/\/doi.org\/10.1128\/aac.47.9.2933-2937.2003","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,9]]},"assertion":[{"value":"2003-02-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-06-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}